3M Company has filed a shelf registration that allows it to offer debt securities and common stock from time to time after the registration becomes effective. Future offerings may be made through underwriters, dealers, agents, or directly to investors, with specific terms set in prospectus supplements.
3M states that net proceeds from any sales will generally be used for corporate purposes and may be temporarily invested in marketable securities. The filing incorporates 3M’s latest annual report, proxy materials, and future Exchange Act reports by reference and directs investors to detailed risk factors in those documents.
3M Company filed its 10-K reporting 2025 net sales of $24,948 million, up 1.5%, with organic sales up 0.9%. GAAP operating margin was 18.6% and adjusted margin 23.4%, reflecting productivity gains but also higher PFAS-related litigation and transformation costs.
GAAP EPS was $6.00, down 17%, while adjusted EPS rose 10% to $8.06, helped by lower restructuring, growth investments and a gain on an investment. 3M completed its exit from PFAS manufacturing by year-end 2025, continues to manage substantial PFAS liabilities including the PWS Settlement of $10.5–$12.5 billion through 2036, and will contribute $6.0 billion under the Combat Arms Earplug settlement through 2029.
The company spun off its Health Care business as Solventum in 2024, now reported as discontinued operations, and is managing related dis-synergies and transition agreements. 3M maintained a global footprint with about 60,500 employees and repurchased 3.4 million shares in Q4 2025 under a $7.5 billion buyback authorization.
3M director James R. Fitterling reported a routine compensation deferral into stock equivalents. On January 23, 2026, an entity described as a corporation associated with him acquired 287.929 shares of 3M common stock equivalents at $160.63 per share, recorded as indirect ownership "By Corporation". According to the plan footnote, this non‑employee director elected to defer compensation into a common stock equivalents account under 3M’s Compensation Plan for Non‑Employee Directors and has no voting or investment powers over that account.
After this transaction, the corporation‑held indirect position is shown as 6,475.503 common stock equivalents. The filing also lists 11,412.005 shares of common stock held directly and 200 shares held indirectly By Spouse, which are reported holdings rather than new transactions.
A holder of the issuer’s common stock has filed a Form 144 notice to sell 1,857 shares, with an aggregate market value of 294390.77, through Fidelity Brokerage Services LLC on or around 01/22/2026 on the NYSE. The filing states that there are 531,225,048 shares of this class outstanding.
The shares to be sold were acquired on 12/01/2025 via restricted stock vesting from the issuer as compensation, with full vesting and payment occurring on that date. The section covering securities sold during the past three months does not list any prior sales for this person, and by signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.
3M Company filed a current report describing that it has released its fourth-quarter 2025 and full-year 2025 financial results. The company also provided its full-year 2026 guidance in a press release dated January 20, 2026, which is included as an exhibit to the report. This filing mainly serves to formally furnish that earnings press release and related outlook information to investors and regulators.
3M Company executive Victoria Clarke reported equity transactions involving 3M common stock. On December 1, 2025, she acquired 2,846 shares of 3M common stock at $170.48 per share through the vesting and settlement of restricted stock units, and disposed of 989 shares of common stock at the same price. After these transactions, she beneficially owned 2,219.831 shares of 3M common stock in direct form. The filing also notes that she holds 2,845 restricted stock units, each representing a contingent right to receive one share of 3M common stock, with these units scheduled to vest in three equal annual installments beginning December 1, 2024.
3M (MMM) insider transaction: EVP & Chief HR Officer Zoe L. Dickson exercised 13,629 non-qualified stock options at $138.39 per share on 11/13/2025 and sold 13,629 common shares the same day in multiple trades.
The sales were executed in increments at prices ranging from $169.70 to $169.935 per share. Following these transactions, beneficial ownership stood at 6,161.5219 shares held directly and 298 shares held indirectly via a 401k/paesop Trust. The option covered 13,629 underlying shares granted on 02/04/2021 and expiring on 02/03/2030.
3M (MMM) reported insider activity by EVP & Chief HR Officer Zoe L. Dickson on 11/13/2025. She exercised non-qualified stock options for 5,076 shares at $154.69 and 8,750 shares at $154.04, then executed multiple open‑market sales the same day at prices around $169.72–$169.86.
Following these transactions, she held 6,161.5219 shares directly and 298 shares indirectly via a 401k/PAESOP trust. Footnotes note that direct holdings include dividend share equivalents accrued under 3M’s Deferred Compensation Plan and shares acquired under the General Employee Stock Purchase Plan.
3M (MMM) filed a Form 144 notice for the proposed sale of 27,455 shares of common stock, showing an aggregate market value of 4,661,909.39. The sales are listed through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 11/13/2025.
The shares relate to option grants dated 02/07/2017 (5,076 shares), 02/04/2020 (13,629), and 02/02/2021 (8,750), noted as acquired on 11/13/2025 for cash. Shares outstanding were 531,225,048.